RETA-3 20MG – Retatrutide Research Material

RETA-3 20MG is a research-use-only material containing retatrutide, also identified in scientific literature as LY3437943. Retatrutide is an investigational peptide compound being studied for its interaction with three hormone receptor systems: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.

Retatrutide Research

Retatrutide has become an important subject of scientific research because of its distinctive triple-receptor activity. Unlike compounds that act primarily on one or two receptor pathways, retatrutide is designed to activate GIP, GLP-1, and glucagon receptors. Researchers continue to investigate how these combined pathways influence metabolic and endocrine signaling.

RETA-3 20MG is offered as a research material for qualified laboratory and analytical applications. Researchers should establish appropriate experimental procedures, analytical methods, handling practices, and storage requirements according to their institutional protocols and applicable regulations.

Research-Grade Peptide Material

Peptide research requires clearly identified materials and controlled laboratory conditions. RETA-320MG is presented for researchers conducting controlled investigations involving peptide compounds and receptor-related biological pathways.

The product should be handled only by appropriately trained personnel using suitable laboratory procedures. Researchers are responsible for determining whether the material is appropriate for their particular experimental application.

Retatrutide and Receptor Research

Retatrutide, or LY3437943, is being investigated as a single molecule capable of activating GIP, GLP-1, and glucagon receptors. Eli Lilly’s current research pipeline identifies retatrutide as an investigational GIP/GLP-1/glucagon receptor agonist being studied in several clinical research programs.

Published research has also examined the molecular interactions between retatrutide and these three receptor systems, providing researchers with additional information about its pharmacological characteristics.

Laboratory Research Use Only

RETA-3 20MG is intended strictly for laboratory research and analytical purposes. It is not intended for human consumption, self-administration, diagnosis, treatment, prevention, or mitigation of disease.

Retatrutide remains an investigational compound. As of the latest information from Eli Lilly, it has not received FDA approval and remains under clinical investigation.

For this reason, RETA-320MG should not be marketed or described as an approved medication or as a treatment for obesity, diabetes, weight management, or other medical conditions.

Why Researchers Study Retatrutide

The three-receptor activity of retatrutide makes it a significant subject for research involving metabolic signaling and hormone receptor biology. Studies have investigated its effects and mechanisms in controlled research settings, while ongoing clinical development continues to examine its potential applications.

RETA-3 20MG provides a clearly identified research material for qualified laboratories interested in studying retatrutide and its associated receptor pathways.

Important Research Notice

RETA-320MG is supplied for research purposes only. It is not intended for human or veterinary use and should be handled according to applicable laboratory safety procedures and institutional requirements.

Retatrutide is an investigational compound and is not currently an FDA-approved medication.